Merck Acquires Terns Pharma in $5.8 Billion Deal Advancing TERN-701 Toward Pivotal CML Trials

With TERN-701 now carrying FDA Breakthrough Therapy Designation for Philadelphia chromosome-positive chronic myeloid leukemia, Merck's $5.8 billion close of the Terns Pharma acquisition signals an accelerated CMC planning timeline that manufacturing and regulatory teams will need to absorb quickly.

The designation, granted to TERN-701 for adult Ph+ CML patients, activates more intensive FDA guidance and rolling review eligibility, compressing the window between late-stage development and the chemistry, manufacturing, and controls submissions that underpin a BLA. For plant heads and QA directors, that compression means process validation strategies and analytical method transfers should be scoped now, not at pivotal-trial completion.

Breakthrough Therapy Designation carries defined FDA interaction commitments, including more frequent meetings and cross-disciplinary review. Regulatory affairs leads inheriting this asset will need to align CMC documentation cadence with those touchpoints, particularly around 21 CFR Part 211 compliance for any new or transferred manufacturing sites brought into the Merck network post-close.

The $5.8 billion consideration reflects the commercial and clinical weight Merck places on the CML franchise. TERN-701 is a next-generation BCR-ABL inhibitor, a class where manufacturing complexity, particularly polymorphic form control and impurity profiling, has historically drawn FDA scrutiny during pre-approval inspections. Integrating Terns' existing CMC package into Merck's quality systems under ICH Q10 will be a near-term operational priority.

Supply chain continuity for clinical trial material also warrants early attention: pivotal trials demand consistent drug substance and drug product supply, and any site qualification or tech transfer initiated post-acquisition adds lead time that Breakthrough designation's accelerated review schedule will not absorb on its own.

The pace at which Merck files a pivotal-trial IND amendment and advances toward a BLA submission will serve as the measurable checkpoint for how effectively the post-acquisition CMC integration was executed.

Source: Media4Growth via Indian Pharma Post, 6 May 2026.